Ligação por videoconferência
19 DE ABRIL (Quarta-feira)
SALA L7 (PISO 1, EDIFÍCIO NASCENTE) DO CENTRO DE INVESTIGAÇÃO MÉDICA DA FMUP (CIM-FMUP)
14:00Classificação e Conceitos Fundamentais das Doenças Pulmonares Difusas (DPD)
António Morais
Serviço de Pneumologia do CHUSJ
15:00Avaliação e Interpretação dos Padrões Imagiológicos e o seu Enquadramento no Diagnóstico das DPD
José Miguel Pereira, Rui Cunha e André Carvalho
Serviço de Radiologia do CHUSJ
17:00Intervalo
17:30Diagnóstico Clínico e Analítico das Doenças Reumáticas Sistémicas
Raquel Miriam Ferreira
Serviço de Reumatologia do CHUSJ
18:30Estudo genético na abordagem diagnóstica nas doenças pulmonares difusas
Ana Grangeia e Patrícia Mota
Departamento de Patologia da FMUP | Serviço de Pneumologia do CHUSJ
20 DE ABRIL (Quinta-feira)
SALA L7 (PISO 1, EDIFÍCIO NASCENTE) DO CENTRO DE INVESTIGAÇÃO MÉDICA DA FMUP (CIM-FMUP)
09:00Processamento e Interpretação do Lavado Broncoalveolar e o seu Enquadramento no Diagnóstico das DPD
Marília Beltrão, Oksana Sokhatska e Luís Delgado
Departamento de Patologia da FMUP
10:30Intervalo
11:00Técnicas Endoscópicas orientadas para o diagnóstico das DPD
Hélder Novais e Bastos
Serviço de Pneumologia do CHUSJ
Biópsia Pulmonar Cirúrgica no contexto das DPD
Pedro Fernandes
Serviço de Cirurgia Torácica do CHUSJ
Avaliação da Qualidade da Amostra e das Alterações Histológicas da Biópsia Pulmonar nas DPD
Conceição Souto Moura e Susana Guimarães
Serviço de Anatomia Patológica do CHUSJ | Departamento de Patologia da FMUP
13:30Almoço
14:30Transplante Pulmonar nas DPD
Carla Damas
Consulta de Transplante Pulmonar do Serviço de Pneumologia do CHUSJ
15:30Papel do enfermeiro na abordagem e monitorização das DPD
Luciana Oliveira
Centro de Ambulatório do CHUSJ
16:30Intervalo
17:00Cuidados Paliativos no contexto das DPD
Conceição Pires
Serviço de Cuidados Paliativos do CHUSJ
18:00Discussão de Casos Clínicos
21 DE ABRIL (Sexta-feira)
AULA MAGNA DA FMUP
https://med-up-pt.zoom.us/j/99715239088?pwd=Z1FQcWdsVjA3cjBTcTlBYWFoRUJMQT09
09:00Progressive Pulmonary Fibrosis in Adults-An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Katerina M. Antoniou
Laboratory of Molecular and Cellular Pneumonology, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Greece
09:30What is progression and how do we best capture it?
Peter George
Department of Interstitial Lung Disease, Royal Brompton Hospital, London, UK, National Heart and Lung Institute, Imperial College London, London, UK
10:00Lung Function advantages and pitfalls in the progression criteria
Athol Wells
Interstitial Lung Disease/Sarcoidosis Unit, Royal Brompton Hospital, London, UK
10:30Lung Function: Interpretation and Technical Standards
Andrea Aliverti
Dept of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milan, Italy
11:00Coffee-break
11:30Imaging in Progressive Pulmonary Fibrosis
To be announced
12:00Antifibrotics in Fibrotic Interstitial Lung Diseases, present and future
Vincent Cottin
Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, member of ERN-Lung; University of Lyon, INRAE, IVPC, France
12:30What is the best management before the progression of fibrosis?
Elisabetta Renzoni
Interstitial Lung Disease Unit, Royal Brompton and Harefield Clinical Group, Guy’s and St Thomas’ NHS Foundation Trust, London; Margaret Turner Warwick Centre for Fibrosing Lung Diseases, NHLI, Imperial College, London, UK
13:00Lunch
14:30Usual interstitial pneumonia as a stand-alone diagnostic entity: the case for a paradigm shift?
Moises Selman
Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Ciudad de México, México
15:00Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement
Vincent Cottin
15:30Interstitial Lung Abnormalities- Diagnosis and Management
Gary Hunninghake
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, Harvard Medical School, Boston, MA, USA
16:00Break
Rare Diffuse Lung Diseases Corner
16:30ILD in lysosomal storage disorders
Raphael Borie
Service de Pneumologie A, INSERM UMR_1152, Centre de Référence des Maladies Pulmonaires Rares, FHU APOLLO, APHP Hôpital Bichat, Sorbonne Université, Paris, France
17:00Is SARSCov2 a cause of Fibrotic ILD?
Katerina M. Antoniou
17:30Chronic interstitial lung disease in children. Diagnosis and Management
Matthias Griese
Hauner Children’s Hospital, University of Munich, German Center for Lung Research, Munich, Germany
22 DE ABRIL (Sábado)
AULA MAGNA DA FMUP
https://med-up-pt.zoom.us/j/99715239088?pwd=Z1FQcWdsVjA3cjBTcTlBYWFoRUJMQT09
09:00ERS guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases
Venerino Poletti
Pulmonology Unit, Thoracic Diseases Dept, G.B. Morgagni Hospital, Forli, Italy; Dept of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
09:30Do we already know what really is Pleuroparenchymal Fibroelastosis and how to proceed?
Elisabetta Renzoni
10:00Familial Pulmonary Fibrosis- ERS Guidelines and Genetic Testing
Raphael Borie
10:30Rheumatoid Arthritis Interstitial Lung Disease management and treatment
Leticia Kawano Dourado
HCor Research Institute, Hospital do Coração, São Paulo, Brazil; Pulmonary Division, Heart Institute (InCor), University of Sao Paulo Medical School, São Paulo, Brazil; INSERM, University of Paris, Paris, France
11:00Break
11:30Hypersensitivity Pneumonitis Immunopathology and its implication on the diagnosis
Maria José Cruz
Servei de Pneumologia, Vall d´Hebron Institut de Recerca (VHIR), Barcelona, Spain; Instituto de Salud Carlos III, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
12:00Hypersensitivity pneumonitis: A new strategy for serodiagnosis and environmental surveys
Adeline Rouzet
Department of Parasitology Mycology, University Hospital of Besançon, UMR/CNRS 6249 Chrono-Environnement Research Team, University of Bourgogne Franche-Comté, Besançon, France
12:30Pulmonary Hypertension in Fibrotic ILD. Do we have a new paradigm?
Steven Nathan
Advanced Lung Disease and Transplant Program, Inova Heart and Vascular Institute, Falls Church Virginia USA
